RCKTW Rocket Pharmaceuticals, Inc. Warrant
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Employees
- 202
- List Date
- 2023-02-27
- CIK
- 0001281895
- Headquarters
- New York, NY
- Homepage
- https://www.rocketpharma.com
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|
| Jan | -- | -45.63% | 59.31% | -7.02% | 2.22% |
| Feb | -20.00% | -3.70% | -19.09% | 79.75% | 9.24% |
| Mar | -33.28% | 10.41% | -32.08% | -28.09% | -20.76% |
| Apr | -2.55% | -50.37% | 28.21% | -33.56% | -14.57% |
| May | 86.67% | 47.90% | -39.45% | -3.00% | 23.03% |
| Jun | -32.12% | -48.03% | 42.75% | -50.00% | -21.85% |
| Jul | 40.50% | -11.05% | 2.06% | -53.33% | -5.46% |
| Aug | -47.89% | 70.21% | 15.65% | -87.50% | -12.38% |
| Sep | 13.33% | -14.63% | -1.26% | 1900.00% | 474.36% |
| Oct | -27.27% | -4.43% | 9.62% | -- | -7.36% |
| Nov | 180.00% | -34.44% | 0.00% | --* | 48.52% |
| Dec | 13.95% | 24.27% | -27.89% | -- | 3.44% |
| Total | 26.90% | -77.81% | -10.62% | -54.81% | -29.08% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report: RCKTW
Executive Summary
Executive Assessment: NEUTRAL with confidence level 6/10
Key Drivers:
- Recent news headlines indicate a high risk of potential stock price manipulation due to investor lawsuits.
- Technical indicators suggest the stock is in a neutral regime, but volatility remains high.
Primary Risks:
- High beta value (3.11) indicates increased volatility and sensitivity to market movements.
- Lack of earnings data makes it challenging to assess the company's financial performance.
Investment Thesis:
RCKTW appears to be trading based on recent news headlines rather than fundamental analysis. The stock's high volatility and lack of earnings data create uncertainty around its potential for growth or decline.
Recent News Sentiment Impact:
The negative sentiment from recent news headlines (lawsuits and investor losses) has likely contributed to the stock's neutral-to-bearish trend direction.
Technical Analysis
Trend Direction: Neutral, with a slight bearish bias due to recent MACD signal line crossover.
Support/Resistance Levels:
- Lower band: $-0.00
- Middle band: $0.00
- Upper band: $0.00
Momentum Signals:
- RSI interpretation: 50.40, indicating a neutral regime.
- MACD signal: Bearish crossover suggests potential downside continuation.
- Bollinger Bands position: Neutral, as the stock is trading within the middle band.
Volume Analysis:
- Volume SMA 20: 223965.05
- On-Balance Volume (OBV): -286564.00
- Volume Rate of Change: 1499.10%
News & Sentiment Analysis
Recent Headlines Summary: Negative sentiment dominates recent news headlines, focusing on lawsuits and investor losses.
Sentiment Assessment: Negative sentiment prevails, suggesting potential pressure on the stock price.
Catalyst Identification: No clear catalysts identified; recent news appears to be driving the stock's trend direction.
Market Narrative: The market narrative is focused on negative news headlines, which may have contributed to the stock's neutral-to-bearish trend direction.
Risk & Volatility Assessment
Beta Interpretation: High risk due to beta value (3.11) indicating increased volatility and sensitivity to market movements.
Volatility Regime: Current volatility regime is high, with a historical volatility of 853.2%.
Options Market Signals:
- IV rank: N/A
- Put/call ratios: N/A
- Unusual activity: No data available
Downside Protection: Support levels are not well-defined due to the stock's recent price action.
Market Context & Positioning
Sector Performance: RCKT is trading in line with its sector average, exhibiting a neutral performance.
Institutional Activity: No clear institutional interest signals identified.
Correlation Analysis: Correlation coefficient (0.02) suggests minimal correlation between the stock and market trends.
Relative Valuation: The stock appears overvalued based on recent price action and lack of earnings data.
Key Levels & Action Items
Critical Price Levels:
- Support: N/A
- Resistance: N/A
Breakout/Breakdown Levels: No clear levels identified due to the stock's recent price action.
Time-Sensitive Catalysts: No upcoming events or catalysts identified.
Risk Management: Consider a stop-loss order around $0.00, with a position size adjusted according to risk tolerance.
Please note that this report is based on the provided data and does not contain buy/sell advice. The analysis focuses on risk/reward considerations and technical signal interpretation.
RCKTW Options Activity & IV Rank
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
IV(call wing) − IV(ATM), in vol pointsThe same measure on the upside: how the OTM call is priced against the at-the-money strike.
- Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
- Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Loading the implied volatility surface…
Loading the implied volatility smile…
Risk Metrics
Analysis Details
Data Points: 158
Period: 252 trading days
High volatility - stock moves more than market
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $2K | #6268 of 6285 | +0.1% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
RCKTW Institutional Ownership (13F)
Filings for 2026-06-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Simplex Trading, LLC Custodian | $453.41K | 80.45% | 2026-09-30 |
| 2 | GROUP ONE TRADING LLC Custodian | $110.20K | 19.55% | 2026-09-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Simplex Trading, LLC Custodian | $8.15K | 100.00% | 2026-09-30 |
RCKTW Insider Trading (Form 4)
Latest: 2026-05-28| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-05-28 | John Militello | See Remarks | Mixed | −121,694 opt | — | EDGAR | |
| 2026-05-26 | Gaurav Shah | CEO | Mixed Sell −55,684 · Exer +76,490 |
+20,806 | $2.28 | -$42.5K | EDGAR |
| 2026-05-21 | John Militello | See Remarks | Sell (S) | −384 | $3.01 | -$1.2K | EDGAR |
| 2026-05-21 | Martin Wilson | General Counsel | Sell (S) | −662 | $3.01 | -$2.0K | EDGAR |
| 2026-05-21 | Gaurav Shah | CEO | Sell (S) | −2,409 | $3.01 | -$7.3K | EDGAR |
| 2026-05-14 | John Militello | See Remarks | Sell (S) | −855 | $3.61 | -$3.1K | EDGAR |
| 2026-05-14 | Martin Wilson | General Counsel | Sell (S) | −3,361 | $3.61 | -$12.1K | EDGAR |
| 2026-05-14 | Gaurav Shah | CEO | Sell (S) | −2,728 | $3.61 | -$9.8K | EDGAR |
| 2026-05-11 | Sarbani Chaudhuri | See Remarks | Sell (S) | −17,650 | $3.84 | -$67.7K | EDGAR |
| 2026-02-20 | John Militello | See Remarks | Sell (S) | −1,157 | $3.34 | -$3.9K | EDGAR |
| 2026-02-20 | Gaurav Shah | CEO | Sell (S) | −5,990 | $3.34 | -$20.0K | EDGAR |
| 2026-02-20 | Martin Wilson | General Counsel | Sell (S) | −1,376 | $3.34 | -$4.6K | EDGAR |
| 2026-02-18 | John Militello | See Remarks | Sell (S) | −3,726 | $3.31 | -$12.3K | EDGAR |
| 2026-02-18 | Martin Wilson | General Counsel | Sell (S) | −12,253 | $3.31 | -$40.6K | EDGAR |
| 2026-02-18 | Gaurav Shah | CEO | Sell (S) | −12,279 | $3.31 | -$40.7K | EDGAR |
RCKTW Insider Holdings
20 insiders · @ $0.00| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | RTW INVESTMENTS, LP | Director | 18,236,124 | $36.5K | $0 | 3 | 2025-09-23 |
| 2 | Roderick Wong | Director | 18,236,124 | $36.5K | $0 | 5 | 2025-07-18 |
| 3 | Gaurav Shah | CEO | 1,467,962 | $2.9K | -$1.70M | 23 | 2026-05-26 |
| 4 | Gotham Makker | Director | 1,036,846 | $2.1K | -$16.35M | 8 | 2025-07-18 |
| 5 | Martin Wilson | General Counsel | 677,977 | $1.4K | -$435.4K | 20 | 2026-05-21 |
| 6 | Kinnari Patel | See Remarks | 573,628 | $1.1K | -$472.4K | 16 | 2025-05-22 |
| 7 | Christopher James Stevens | Chief Operating Officer | 469,129 | $938 | $0 | 2 | 2026-02-13 |
| 8 | Syed Ali-aamir Rizvi | Chief Medical Officer | 407,874 | $816 | $0 | 2 | 2026-02-13 |
| 9 | Jonathan David Schwartz | See Remarks | 299,064 | $598 | -$288.3K | 8 | 2025-11-20 |
| 10 | Sarbani Chaudhuri | See Remarks | 267,510 | $535 | -$67.7K | 2 | 2026-05-11 |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
RCKTW vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.23T | 43.9 | +45.5% | +25.2% | 35 |
| JNJ Johnson & Johnson | $656.5B | 40.5 | +7.8% | +28.8% | 94 |
| ABBV ABBVIE INC. | $505.6B | 48.8 | +10.7% | +23.7% | 50 |
| MRK Merck & Co., Inc. | $339.7B | 137.1 | +4.9% | +24.9% | 58 |
| NVS Novartis AG | $293.1B | — | — | +9.3% | 28 |
| AZN AstraZeneca PLC | $277.2B | — | — | +91.5% | 20 |
| ABT Abbott Laboratories | $181.0B | 38.6 | +10.0% | −16.1% | 29 |
| NVO Novo-Nordisk A/S | $173.8B | — | — | −25.7% | 24 |
| RCKTW Rocket Pharmaceuticals, Inc. Warrant | — | — | — | −88.3% | — |
| Peer median | $316.4B | 43.9 | +10.0% | +24.3% | 32 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.